CTLA4 and non-small cell lung carcinoma: In many cancers such as non-small cell lung cancer (19), melanoma (20), renal cell carcinoma (21), and hepatocellular carcinoma (22), immune checkpoint inhibitors such as CTLA4 inhibitors and PD-1 inhibitors have been shown to have significantly positive effects on patient survival.